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Background: Patients with lung cancer (LC) report lower quality of life (QoL) and
higher levels of psychological distress compared with other cancer populations. Lung
cancer stigma (LCS) may in part explain these findings.
Aim: We investigated the prevalence of patient‐perceived lung cancer stigma (LCS)
and its relationships to symptom burden/severity, depression, and deficits in health‐
related quality of life (HR‐QoL).
Methods: In this descriptive, observational, and cross‐sectional study, 201
participants were sent questionnaires. These included the Cataldo Lung Cancer
Stigma Scale (CLCSS), the Lung Cancer Symptom Scale, the Centre for Epidemiologic
Studies‐Depression Scale, and the Quality of Life Inventory.
Results: Participants were on average 69 years old, 52% women, 95% ever
smokers, and 18.5% current smokers. The mean total CLCSS score was 53.1
(SD = 14.1; range = 31‐94). LCS was significantly correlated with younger age
(P < .001), greater social deprivation (P < .05), being unemployed (P < .001), depres-
sion (P < .001), symptom burden (P < .001), and HR‐QoL deficits (P < .001). Symptom
burden explained 18% of variance in LCS (P < .001). LCS explained 8.5% and 14.3% of
the variance in depression (P < .001) and HR‐QoL (P < .001), respectively.
Conclusion: Patients with lung cancer are vulnerable to LCS. Symptom burden can
directly contribute to greater perceived LCS. Greater perceived LCS can be directly
related to greater levels of depression and lower HR‐QoL. A tailored approach is
required to screen for LCS and implement interventions to enhance the psychosocial
well‐being of patients with perceived LCS.
KEYWORDS
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Compared with patients with a history of other cancers, patients with
lung cancer (LC) are more likely to report only fair or poor health, and
exhibit significant psychological problems.1 Psychological morbidity
has been associated with increased symptom burden and lack of social
support,2 being the precursor of poor health‐related quality of life
(HR‐QoL) and increased risk for mortality.3 Specific to LC, up to 55%wileyonlinelibrary.com/jourof patients may meet the criteria for clinical depression.4 In addition,
the association between depression and mortality is stronger amongst
patients exhibiting more symptoms and those who report less
social support.2
Psychological morbidity in patients with LC may have its origins in
perceived lung cancer stigma (LCS). In his classic work about stigma,
Goffman5 defined stigma as “an attribute that is deeply discrediting.”
This can result in patients feeling unjustly blamed for their illness© 2019 Wiley Periodicals, Inc.nal/cnr2 1 of 11
2 of 11 MAGUIRE ET AL.and particularly stigmatised because the disease is so strongly associ-
ated with smoking.6,7 Blame has often been cited as a major stressor
of having LC.8,9 Indeed, patients with LC are more likely to report
internal causal attributions for their cancer than patients with breast
or prostate cancer.10 Previous US‐based research has demonstrated
a link between LCS and poor patient outcomes. Specifically, LCS was
associated with greater depressive symptomatology,11-13 poorer HR‐
QoL,12 and higher symptom severity.4 Furthermore, LCS was found
to account for unique and significant variability of 5%, 1.2%, and
1.3% in depression,13 HR‐QoL,11 and symptom severity,4 respectively.
Health‐related stigma is a culturally derived phenomenon.14 There-
fore, it is important to understand the effects of perceived LCS in a UK
sample to inform health care providers of the needs of their patients
with the intention to develop support pathways for these patients.
To date, studies that quantify LCS are limited to studies from the
USA and Australia.11,15-18 No research has been conducted in the
United Kingdom to explore LCS and its relationship with symptom
burden/severity, depression, and HR‐QoL. Investigating and under-
standing these relationships is a necessary first step to facilitate the
development of possible targeted LCS interventions. This study aimed
to address this existing gap in knowledge in the UK as follows.1.1 | Aims and hypothesis
Our aim was to investigate the prevalence of patient‐perceived LCS
and the role of LCS as a covariate of symptom severity and/or burden,
depression, and HR‐QoL.
We aimed to address the following research questions:
1. What are the prevalence and characteristics of perceived LCS in
LC patients in Scotland?
2. What are the effects of LC symptom severity and/or burden on
perceived LCS, controlling for patient sociodemographic character-
istics and clinical variables?
3. What are the effects of perceived LCS on depression,
controlling for patient sociodemographic characteristics and
clinical variables?
4. What are the effects of perceived LCS on HR‐QoL, controlling for
patient sociodemographic characteristics and clinical variables?
We specifically hypothesised that greater symptom burden and/or
severity would be adversely related to greater perceived LCS. In turn,
greater perceived LCS would be associated with greater levels of
depression and lower HR‐QoL.2 | METHODS
2.1 | Study design and setting
We conducted a descriptive, observational, cross‐sectional study. We
recruited a convenience sample of patients with LC from two NHSHealth Boards in Scotland, and within these Boards, recruitment took
place at six regional hospitals. Reporting of the study was guided
by the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) Statement (Von Elm et al, 2014).2.2 | Eligibility criteria
Potential participants had to (a) be aged ≥18 years, (b) have a clinical
diagnosis of LC, (c) be able to understand study information, and (d) be
physically and psychologically fit to participate as deemed by a
member of the health care team. We excluded patients unable to meet
any of the above criteria.2.3 | Procedures
The study received a favourable ethical opinion from the NRES Com-
mittee East of England ‐ Norfolk (Ref 14/EE/1099). Health profes-
sionals identified potential participants during routinely scheduled
clinic visits. They briefly outlined the purposes of the study and
provided a study pack which contained the patient information sheet,
a consent form to be contacted for research interviews (details
reported elsewhere), self‐reported questionnaires, and a stamped
envelope to return the completed pack anonymously to the
researcher. Completion of the questionnaires acted as study consent.
If the patient did not return the study packs within 14 days, a reminder
letter was sent.2.4 | Outcome measures
2.4.1 | Cataldo Lung Cancer Stigma Scale (CLCSS)
The CLCSS is a valid and reliable measure to assess the experiences of
stigma.12 It comprises 31 items and four subscales (stigma and shame,
social isolation, discrimination, and smoking) that are rated on a
four‐point Likert scale (“strongly disagree,” “disagree,” “agree,” and
“strongly agree”). A higher score indicates greater experience of stigma
(possible score range 31‐124). Cronbach's alpha was 0.93. Construct
validity was demonstrated with expected relationships with depres-
sion in our study as well as other studies.12,132.4.2 | Lung Cancer Symptom Scale (henceforth “LC
symptom scale”)
The LC symptom scale measures the severity of LC specific symptoms
and has demonstrated good reliability and content validity.19 The scale
has nine items (rated from 0 to 100), which measure symptoms,
symptom burden, and symptom severity. Higher scores indicate
greater symptom severity. Cronbach's alpha was 0.84.
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Scale (CES‐D)
The CES‐D is a widely used tool to assess depression, with established
validity and reliability in a wide range of populations including can-
cer.20 Twenty items are rated on a four‐point scale. Higher scores indi-
cate greater depression (score range 0‐60). Cronbach's alpha was 0.89.2.5 | Quality of Life Inventory (QLI)
The QLI has four subscales (physical, psychological, social, and
spiritual) and consists of 33 items.21 This measure was previously
validated with a population with LC.22 Higher scores indicate better
HR‐QoL (score range 0‐10). Cronbach's alpha was 0.91.
We collected self‐reported sociodemographic information (eg,
smoking history) and clinical data from case note review, including
LC type and stage, presenting symptoms, mode of presentation, date
of diagnosis, time since being diagnosed, previous treatment for LC,
current management/treatment of LC, and any comorbidities.2.6 | Data analysis
We first investigated the factor structure of the CLCSS in our sample
to account for any cultural diversity compared with the original factor
structure based on US‐based data.12 Compared with Cataldo et al12
who reported a four‐factor structure (Stigma and Shame, Social Isola-
tion, Discrimination, and Smoking), our analyses resulted in five factors
(Social Isolation, Smoking, Stigma and Shame, Health care provider
Stigma, and Discrimination) (Table 1). The number of items in the scale
per factor is reported in Table 1 (see Supplementary file S1 and Figure
S2 for details).
Descriptive statistics and graphs were used to analyse CLCSS data.
Frequency counts and percentages of responses were generated to
describe response patterns and quantify missing data. Total and
subscale CLCSS scores were treated as interval‐ratio variables and
are presented as means, standard deviation, and range.
Bivariate associations were explored between sociodemographic
characteristics and clinical factors (interval‐ratio or categorical), and
all patient outcome variables (interval‐ratio). Relationships between
variables were determined using two‐sample t‐test, one‐way analysisTABLE 1 Descriptive statistics for the CLCSS total and component score
CLCSS Component (N = 201) N Items M
Component 1—Social isolation 14 2
Component 2—Smoking 3
Component 3—Stigma and shame 8 1
Component 4—Health care provider stigma 2
Component 5—Discrimination 4
Scale 31 5
Abbreviation: CLCSS, Cataldo Lung Cancer Stigma Scale.of variance, or correlation coefficient calculation. Relationships
amongst patient outcome variables were tested through correlation
analysis. The functional form of these relationships and any necessary
transformations were explored and assumptions of normality checked.
Sociodemographic characteristics and clinical factors statistically
significantly associated with patient outcome variables were retained
and their effects controlled for in subsequent hierarchical regression
modelling to investigate: (a) the effects of LC symptom burden on
perceived LCS and (b) the effects of perceived LCS on depression
and HR‐QoL after controlling for significant sociodemographic and
clinical covariates identified in the previous step. Assumptions relating
to the normal distribution of errors and multicollinearity were investi-
gated; no modifications to the analysis were required. Cumulative R2
and R2 change (ΔR2) was reported for each model to indicate
the unique contribution of each predictor variable in explaining the
variance of each dependent variable. The level of significance
was set at 0.05. IBM SPSS (IBM Inc. Chicago, IL) was used for the
statistical analysis.3 | RESULTS
From 368 potential participants approached, 201 (54.6%) returned
questionnaire packs. Case notes were accessible and reviewed
for 195 participants. The total sample had a mean age of
69.2 ± 9.1 years (range 41‐89 years), 52% were women, 63.5% were
married/partnered, and 71.2% were in a cohabitating situation
(Table 2). Ninety‐five percent were ever‐smokers, 18.5% current
smokers, and 76.9% were quitters. The majority of participants had
localised LC (51.9%), non‐small cell LC (91.2%), and received surgery
alone or in combination with systemic treatment (49.7%).3.1 | Prevalence of LCS, symptom severity/burden,
depression, and HR‐QoL deficits
CLCSS score was 53.1 (SD = 14.1; Table 1). Perceptions of LCS
more frequently reflected eight CLCSS items/statements, endorsed
by at least 20% of the sample (Figure 1). Most frequently, respon-
dents agreed/strongly agreed that others assumed that LC was
caused by smoking even if the patient had stopped smoking yearss
ean (SD); Median Actual Range Possible Range
2.1 (7.6); 20.0 14‐48 14‐56
7.6 (2.4); 8.0 3‐12 3‐12
2.6 (4.2); 12.0 8‐26 8‐32
3.6 (1.5); 3.0 2‐8 2‐8
7.2 (2.3); 7.0 4‐16 4‐16
3.1 (14.1); 53.0 31‐94 31‐124
TABLE 2 Characteristics of all study participants (n = 201)
Variable
Mean (SD);
Median
Min‐
Max
Age in years (N = 190) 69.2 (9.1); 70.5 41‐89
Years since diagnosis
(N = 187)
2.6 (1.8); 1.9 0.2‐11.0
Variable N %
Gender (N = 196)
Male 94 48.0
Female 102 52.0
Age categories (N = 190)
41‐50 years 8 4.2
51‐60 years 25 13.2
61‐70 years 62 32.6
71‐80 years 75 39.5
>80 years 20 10.5
Ethnicity (N = 198)
White 196 99.0
Other 2 1.0
Marital status (N = 200)
Married/partnered 127 63.5
Divorced/separated 24 12.0
Widowed 36 18.0
Single 13 6.5
Living status (N = 198)
Alone 57 28.8
With partner/family/friend 141 71.2
Highest educational attainment (N = 197)
Primary school 28 14.2
High school 122 61.9
Higher education college 33 16.8
University 14 7.1
Employment status (N = 199)
Employed (full‐time/part‐time) 24 (18/6) 12.0
Unemployed 17 8.5
Retired 149 75.0
Other (eg, home maker) 9 4.5
Annual income in £ (N = 164)
<10 000 64 39.0
10 001‐20 000 65 39.6
20 001‐50 000 30 18.3
>50 000 5 3.1
Deprivation index (SIMD)a (N = 185)
Fifth 1 (most deprived) 71 38.4
Fifth 2 35 18.8
Fifth 3 29 15.7
(Continues)
TABLE 2 (Continued)
Variable
Mean (SD);
Median
Min‐
Max
Fifth 4 24 13.0
Fifth 5 (least deprived) 26 14.1
Smoking status (N = 195)
Ever smoker 185 94.9
Smoking quitter 150 76.9
Current smoker 36 18.5
Never‐smoker 10 5.1
Symptomatic prior to diagnosis (N = 199)
Yes 153 76.9
Presentation (N = 195)
GP 151 77.4
Emergency 8 4.1
Incidental 36 18.5
Suspected asbestos exposure (N = 197) 36 18.3
Disease status (N = 183)
Local 95 51.9
Locally advanced 52 28.4
Metastatic 31 16.9
Not staged 5 2.8
Treatment (N = 195)
Surgery only 62 31.8
Surgery in combination with other
treatment
35 17.9
Chemotherapy 87 44.6
Radiotherapy 74 37.9
No. of comorbid illnesses (N = 188)
None 40 21.3
One 83 44.1
Two 44 23.4
Three or more 21 11.2
“Local disease” is defined as any tumour that has not spread to the nodes;
“Locally advanced” is defined as the spread to lymph nodes; “Metastatic” is
defined as disease that is not localised and has spread to other parts of the
body.
Abbreviation: SD, Standard deviation.
ahttp://assign‐score.com/estimate‐the‐risk/simd/.
4 of 11 MAGUIRE ET AL.ago (61.7%) or never smoked at all (55.2%). Just over half the
respondents “agreed”/“strongly agreed” that LC is viewed as a self‐
inflicted disease (51.2%). Eighteen per cent revealed that others
had told them that being diagnosed with LC was what they
deserved for smoking. One in five respondents agreed that they felt
guilty for having LC (20%) and felt the need to hide their LC (20%).
Nearly a quarter of participants (23.9%) believed that older people
are less likely to be blamed for LC compared with younger ones, that
health professionals do not take smoker's cough seriously (26.9%),
FIGURE 1 Item‐by‐item prevalence of “agree” or “strongly agree” responses (indicating perceived LCS) on the LCSS
MAGUIRE ET AL. 5 of 11and that they put off seeking medical help because they were
afraid (23.9%).
Symptom burden and symptom severity were low (mean: 31.1,
21.9) (Table 3). Shortness of breath and fatigue were on averageTABLE 3 Descriptive statistics for depression, symptom burden, and HR
Variable (N = 201) Mean (SD); Median
Depression 16.2 (10.9); 14.0
Symptom overall score 32.1 (18.0); 31.6
Symptom burden index 31.1 (17.2); 29.7
Symptom severity 21.9 (5.4); 22.0
Individual symptoms
Appetite loss 31.9 (26.9); 27.0
Fatigue 49.1 (28.3); 49.0
Cough 29.5 (28.5); 21.0
Shortness of breath 49.2 (32.1); 51.0
Haemoptysis 4.8 (12.5); 1.0
Pain 23.0 (29.2); 8.0
Quality of life
Overall score 5.8 (1.4); 5.8
Physical 6.5 (1.8); 6.4
Psychological 5.5 (1.7); 5.6
Social 6.7 (1.9); 7.0
Spiritual 4.7 (2.1); 4.4
Abbreviations: HR‐QoL, health‐related quality of life; LCS, LC Stigma.reported as the most severe symptoms, followed by appetite
loss and cough. Over half (55.2%) of respondents met the criteria
for clinical depression (score > 16). HR‐QoL was moderate to good
on average.‐QoL
Actual Range Possible Range
0‐48 0‐60
0‐84 0‐100
0‐85 0‐100
16‐89 0‐100
0‐96 0‐100
0‐100 0‐100
0‐100 0‐100
0‐100 0‐100
0‐83 0‐100
0‐100 0‐100
0‐9 0‐10
1‐10 0‐10
0‐10 0‐10
0‐10 0‐10
0‐10 0‐10
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Positive correlations were demonstrated with depression, symptom
burden, and all LC symptoms except for appetite loss (Table 4). A
moderate‐to‐strong negative correlation of perceived LCS with overall
HR‐QoL and all HR‐QoL sub‐domains was found.
Negative correlations between LCS scores and sociodemographic
variables were found with age, (Table 4). Positive correlations with
LCS scores were observed for unemployed/homemaker status and
deprivation index. Although not statistically significant, current
smokers reported on average greater perceived LCS than people
who were not currently smokers.
We identified significant relationships of higher levels of depres-
sion with younger age, female gender, living alone, being unemployed
or homemaker, having a low annual income, being a smoking non‐
quitter or a current smoker, lower HR‐QoL, and higher symptom bur-
den (Table 4).
Significant relationships of poorer HR‐QoL with younger age,
being unemployed or a homemaker, being a smoking quitter or a cur-
rent smoker, being symptomatic prior to LC diagnosis, having received
radiotherapy, higher depression levels, and higher symptom burden
were found.3.3 | Symptom burden as a predictor of greater
perceived LCS
Accounting for the effects of age, employment status and social dep-
rivation, and hierarchical regression showed that the overall regression
model of the second step was statistically significant with 18% of the
variance in symptom burden being explained, F(4, 174) = 9.24,
P < .001. More details are shown in Table 5. Incremental R2 for symp-
tom burden was significant (ΔR2 = 0.05).3.4 | Perceived LCS as a predictor of greater patient
depression
Accounting for the effects of covariates, hierarchical regression
showed that the overall regression model of the third step was statis-
tically significant with 22% of the variance in depression being
explained, F(8, 138) = 4.96, P < .001 (Table 6). Sociodemographic char-
acteristics explained 12.1% (P = .006) of the total variance in depres-
sion, clinical factors explained 1.8% (P > .05), and perceived LCS
contributed uniquely and significantly explaining 8.5% (P < .001) of
the total variance in depression.3.5 | Perceived LCS as a predictor of lower patient
HR‐QoL
Accounting for the effects of covariates, hierarchical regression
showed that the overall regression model of the third step was statis-
tically significant with 35% of the variance in HR‐QoL being explained,
F(6, 174) = 15.36, P < .001 (Table 6). Sociodemographic characteristicsexplained 14.4% (P < .001), clinical factors explained 5.9% (P = .005),
and perceived LCS contributed uniquely and significantly explaining
14.3% (P < .001) of the total variance in HR‐QoL.4 | DISCUSSION
These findings support our hypotheses that greater perceived LCS can
be directly associated with greater levels of depression and lower HR‐
QoL amongst patients with a LC diagnosis. Moreover, we were able to
confirm that symptom burden (but not symptom severity) can directly
contribute to greater perceived LCS. These observations have clear
implications for clinical practice and research.
As in previous research,4,11,23 analysis of CLCSS scores indicated
that patients with LC are vulnerable to stigmatisation after diagnosis,
although in this study, mean LCS scores were below the midrange of
the scale. Other studies have shown CLCSS scores of 75 to 102 (vs
53.1 in this study).4,11,16 This observation may indicate that the per-
ceived LCS was generally low in this study's sample. Low scores were
also reported in two Australian samples of LC patients with scores
ranging from 52 to 5517,18 and one American sample with a mean
stigma score of 68.24 In these samples, patients had a confirmed diag-
nosis of LC and were either recruited via oncology clinics18,24 or local
support groups.17 The participants in studies with high stigma scores
recruited a convenience sample via online cancer support websites,
which could have influenced the LCS score because those participants
may not be a typical LC population.
Rose et al18 suggested that the LCS scores were low due to their
sample being newly diagnosed with LC. However, our sample was
diagnosed on average 2.6 years prior to study participation. It could
be suggested that gender may contribute to the findings of different
scores of stigma as those studies with higher scores had a higher pro-
portion of women.4,11,16 However, an Australian study that reported
lower stigma scores had a higher proportion of men18 and another
study with an Australian sample had a higher proportion of women.17
Both genders were evenly presented in this study making gender a
less likely explanation. One factor that studies with lower stigma score
had in common is the age of participants. In these studies, including
the present study, participants' mean age was 65 to 69 years.17,18
However, this observation should be interpreted with caution, as
there is no consensus on what is low or high stigma using the CLCSS.
It may also indicate that participants with high levels of perceived LCS
did not return their questionnaires. A recent study validated a new
LCS tool to establish cut‐off values to identify patients with clinically
meaningful LCS.25 They found a value of 37.5 (possible range of 25‐
125) and above to be clinically meaningful. The evidence is clear that
perceived stigma is associated with poorer psychological well‐being,
and therefore it is important that these patients receive intervention.
Patients who only score high on a few items of the CLCSS resulting
in an overall low score are still expressing perceptions of stigma. Thus,
a lower score should also be recognised, and those patients should be
offered intervention. It is therefore important to establish a meaning-
ful cut‐point to identify patients in need for support. Future research
TABLE 4 Relationships amongst the study variables
Variable LCS Depression HR‐QoL
Age (N = 190) r = −0.28** r = −0.19* r = 0.35**
Time since diagnosis (N = 187) r = 0.09 r = 0.17 r = −0.02
Gender (N = 196) t = 0.08 t = −2.22* t = 0.93
Marital status (N = 200) F = 1.15 F = 1.93 F = 0.75
Living status (N = 198) t = 0.97 t = 2.95** t = −1.23
Highest educational attainment (N = 197) F = 0.57 F = 0.61 F = 0.02
Employment status (N = 199) F = 8.81*** F = 6.88** F = 13.51***
Annual income (N = 164) F = 0.52 F = 4.18* F = 2.28
Deprivation index (SIMD) (N = 185) t = 2.23* t = 1.50 t = −0.79
Ever smoker (N = 195) t = 0.91 t = 1.18 t = −0.97
Smoking quitter (N = 195) t = −1.64 t = −3.43** t = 3.00**
Current smoker (N = 194) t = 1.81 t = 3.56*** t = −3.12**
Symptomatic prior to diagnosis (N = 199) t = 0.20 t = 0.66 t = −1.98*
Presentation (N = 195) F = 0.43 F = 0.26 F = 1.02
Asbestos exposure (N = 197) t = 0.43 t = −1.09 t = 1.08
Localised disease (N = 183) t = −1.55 t = −0.65 t = 1.83
Locally advanced (N = 183) t = 1.20 t = 0.25 t = −1.22
Metastatic disease (N = 183) t = 0.59 t = 0.56 t = −0.93
Surgery only (N = 195) t = −0.32 t = −0.98 t = 1.84
Surgery in combination with other treatment (N = 195) t = 0.75 t = 0.42 t = −0.35
Chemotherapy (N = 195) t = 0.68 t = 0.68 t = −1.18
Radiotherapy (N = 195) t = 0.64 t = 0.90 t = −2.04*
No. of comorbid illnesses (N = 188) F = 0.94 F = 0.17 F = 0.25
Quality of life (N = 201)
Overall score r = −0.52*** r = −0.69** ‐
Physical r = −0.32*** r = −0.61** ‐
Psychological r = −0.49*** r = −0.65** ‐
Social r = −0.52*** r = −0.58** ‐
Spiritual r = −0.18** r = −0.16** ‐
Depression (N = 201) r = 0.40*** ‐ r = −0.69**
Symptom overall score (N = 201) r = 0.29*** r = 0.67** r = −0.67**
Symptom burden index (N = 201) r = 0.26*** r = 0.64** r = −0.61**
Symptom severity (N = 201) r = 0.07 r = 0.10 r = −0.07
Individual symptoms
Appetite loss (N = 201) r = 0.14 r = 0.47** r = −0.42**
Fatigue (N = 201) r = 0.21*** r = 0.56** r = −0.53**
Cough (N = 201) r = 0.19*** r = 0.34** r = −0.31**
Shortness of breath (N = 201) r = 0.15* r = 0.38** r = −0.40**
Haemoptysis (N = 201) r = 0.19*** r = 0.26** r = −0.21**
Pain (N = 201) r = 0.16* r = 0.46** r = −0.46**
“Local disease” is defined as any tumour that has not spread to the nodes; “Locally advanced” is defined as the spread to lymph nodes; “Metastatic” is
defined as disease that is not localised and has spread to other parts of the body.
Abbreviations: G, general practitioner; LCS, LC Stigma; QoL, quality of life; SIMD, Scottish Index of Multiple Deprivation.
*P < .05.
**P < .01.
***P < .001.
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TABLE 6 Summary of hierarchical regression analysis for LCS
predicting depression and QoL
Regression 1—dependent variable: Depression
Step Predictor β ΔR2
1 Sociodemographic characteristics 0.12**
Age −0.07
Female 0.16*
Living alone −0.11
Unemployed or home maker −0.01
Earning <£10 000 annually 0.20
Earning £10 001‐20 000 annually 0.12
2 Clinical factors 0.02
Current smoker −0.15
3 Patient outcome variables 0.09***
Perceived LCS 0.31***
Cumulative R2 0.23***
Regression 2—dependent variable: QoL
Step Predictor β ΔR2
1 Sociodemographic characteristics 0.14***
Age 0.15*
Unemployed or home maker −0.10
2 Clinical factors 0.06**
Current smoker 0.12
Symptomatic prior to LC diagnosis 0.13*
Previous radiotherapy 0.12
3 Patient outcome variables 0.15***
Perceived LCS −0.40***
Cumulative R2 0.35***
Notes: Betas shown are for the last step; Employment status was coded as
a binary variable (unemployed/home maker vs employed/retired).
*P < .05.
**P < .01.
***P < .001.
TABLE 5 Summary of hierarchical regression analysis for symptom
burden predicting LCS
Step Predictor β ΔR2
1 Sociodemographic characteristics 0.13***
Age −0.23**
Unemployed or home maker 0.11*
Most deprived socioeconomic area −0.12
2 Patient outcome variables 0.05***
Symptom burden index 0.22***
Cumulative R2 0.18***
Dependent variable: LCS.
Notes: Betas shown are for the last step; Employment status was coded as
a binary variable (unemployed/home maker vs employed/retired); Social
deprivation was coded as a binary variable (1st fifth vs all other).
*P < .05.
**P < .01.
***P < .001.
8 of 11 MAGUIRE ET AL.could explore the cut‐off points for the CLCSS which are clinically rel-
evant for patients with LC.
Findings for the role of LCS as predictor for depression and poorer
HR‐QoL in patients with LC are consistent with the literature.11,13
Greater scores of stigma were predictive of higher levels of depression
and poorer HR‐QoL. This population has been found to exhibit poorer
psychological well‐being than other cancer populations.26 The present
findings assist in the identification of contributing factors to this high
depressive symptomatology. Although only 8.5% of the variance in
depression was explained by perceived LCS, this significant finding
gives credence to the notion that the social implications and adverse
social experiences of living with LC can well build on patients' feelings
of low mood. It is possible that the longer patients live with perceived
LCS, the greater the chances for them developing chronic depression.
In addition to depression, we found that perceived LCS uniquely
contributed to poorer HR‐QoL. Further research is warranted to
investigate a mediation path that leads from perceived LCS to depres-
sion and subsequently to HR‐QoL, and investigate possible additional
mediators such as social anxiety. Indeed, anxiety has previously been
found to be related to higher levels of stigma.4,11 Anxiety as an addi-
tional stressor could further negatively affect health and increase the
risk for stress‐related illnesses.27
Attempting to identify the actual onset of perceived LCS, we iden-
tified a significant relationship between symptom burden and per-
ceived LCS. Overt symptoms, such as cough, dyspnoea, or
haemoptysis may interfere with social interactions and lead to overt
or covert reactions from others that may trigger experiences of LCS
in patients with LC. These relationships warrant future investigation.
Interestingly, symptom severity did not make a significant contribution
to perceived LCS over and above symptom burden. This may indicate
that even mild symptoms, when manifested during social interactions
and in everyday life (eg, cough, dyspnoea), can be seen as a source
of LCS for patients with LC.28 These relationships have not beenexplored previously in people with LC, but these findings may partly
explain the higher perceived stigma in this group of patients compared
with other cancers.29
Personalised care for patients with LC who manifest perceived LCS
is required. Our findings indicate that patients with poorer socioeco-
nomic backgrounds have higher levels of LCS. Whilst data on smoking
rates across socioeconomic groups exist30 the association with LCS
has not been demonstrated. Stuber et al31 investigated the associa-
tions between smoking stigma and educational status. Their findings
indicate that better socioeconomic background is associated with
higher levels of smoking‐related stigma. It is thought that people with
social deprivation have more exposure to smoke‐free laws32 thus
leading to higher perceived stigma. Their participants were smokers
and nonsmokers from New York City neighbourhoods answering a
survey about relationships between neighbourhood characteristics
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without LC) may explain the difference to our data. Further investiga-
tion of this relationship with LC patients is needed.
We also found that younger patients are more likely to experience
LCS. Older participants may feel less stigma due to the social accept-
ability of smoking when they first started smoking.6 We did not find
a significant difference in perceived LCS between current and past
smokers or non‐smokers. Previous studies also failed to demonstrate
a relationship between smoking status and LCS,16 which is in support
of findings from qualitative research where participants reported LCS
regardless of smoking status.6 Smoking cigarettes is recognised as the
main contributing risk factor for LC, and national and international
health policies have targeted the tobacco industry to attempt to
reduce the burden of this disease. In doing so, this may have come
with a cost: that these health policies lead to experiences of stigma
in people diagnosed with LC.6,31,33 Thus, it is likely that smoking
history is irrelevant for experiences of perceived stigma if people with
LC are being queried about their smoking history by strangers,
acquaintances, or health care professionals after a diagnosis.34
However, there is qualitative evidence that smoking history is relevant
in the experience of internalised stigma.34 It is likely that the small
number of never‐smokers in our study contributed to the lack of
relationship. Associations between smoking status and depression,
however, were significant, and this demonstrates that these patients
have a need for care to address psychological morbidities, whether
this is related to the experience of stigma or not. Further research
should be considered to investigate the role of smoking and the
experience of stigma.
In this study, we, as well as other research groups, have demon-
strated that perceived LCS can originate from various sources and
take various forms.6,15,34-36 Perceived stigma from health care profes-
sionals can be detrimental, as patients can feel discomfort communi-
cating their symptoms to health professionals, which in turn can lead
to delay in presentation, in diagnosis, and in treatment, or even low
uptake of treatment.35,37,38 Supportive and empathetic communica-
tion is important to promote adherence to treatment.39 Furthermore,
shame and blame can also lead to high levels of distress and depres-
sion amongst family members and partners.40,41 Therefore, it is
important not to exclude family members from such discussions, and
to assess for the families'/carers' own perceptions of LCS and how this
may impact on their own feelings. It is thus important for health
professionals to enter into sensitive discussions with patients and
their families to explore the prevalence, nature, and chronicity of
LCS perceptions.
Currently, interventions to reduce stigma amongst these patients
are lacking, but individual counselling or group interventions have
been suggested to help the stigmatized to protect themselves from
the impact of stigma and reduce their vulnerability to encounters of
stigmatisation.42 In this group of patients, a combined intervention
addressing depressive symptomatology and stigma should be consid-
ered because of the relationship between the two. A recent wellness
intervention with patients with LC, which was based on cognitive
behaviour therapy (CBT), focused on psycho‐education, skills in stressreduction, problem‐solving, cognitive challenging, and enhancing rela-
tionship support17 and resulted in improvements in health‐related
stigma, as well as depression and cancer‐specific distress.17
Such interventions may also be delivered via the internet. Online
CBT interventions have been studied in the context of mental health
to treat, for example, depression and anxiety.43 Results demonstrate
that such interventions can achieve similar outcomes as conventional
face‐to‐face delivered therapies.44 Potential benefits of digital inter-
ventions could reduce health costs as less hours of therapists are
required, but this largely depends on the design of the intervention.45
Furthermore, considering the stigma surrounding seeking help for
mental health, the digital setting could overcome the barrier of low
adherence to mental health treatments and increase its reach to
people in need of psychological treatments.464.1 | Strengths and limitations
In this study, we used a relatively large dataset from a patient sample
from six hospitals and with diverse demographic and clinical character-
istics that allowed for statistical examination of relationships amongst
the multiple covariates. However, a large proportion of patients in this
study received surgical treatment which is atypical for this population.
Althoughwe achieved a fairly high response rate, we are unable tomake
comparisons between respondents and nonrespondents to identify
potential bias in our sample and data. It is possible that people who
did feel stigmatised in relation to their LC diagnosis found the study of
greater interest than those who had no LCS perceptions. Alternatively,
those with experiences of LCS may have chosen not to participate.
In addition, we did not collect information on additional covariates
of potential interest, such as self‐esteem, self‐efficacy, anxiety, or
treatment adherence. Therefore, future research should explore the
above factors and their relationships with perceived LCS. Finally, this
was a cross‐sectional investigation of perceived LCS and covariates,
which prevents us from establishing the “causal” pathways that
involve precipitating and perpetuating triggers of LCS and its
longitudinal impact on patient outcomes. Further longitudinal research
is thus warranted.5 | CONCLUSIONS
Perceived LCS is a significant predictor of poorer outcomes (symptom
burden, depression, and HR‐QoL) in patients with LC, when
controlling for demographic and clinical variables. Perceived LCS is a
potentially important psychosocial factor when considering the psy-
chosocial well‐being of patients with LC. Incorporating systematic
assessments of perceived LCS in the plan of care for patients with
LC is required to ensure that adverse effects are tackled in a timely
fashion at the time of diagnosis, during treatment and post‐treatment.
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